Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mannheimia haemolytica antigens are a diverse group of molecular components derived from the Gram-negative bacterium M. haemolytica, the primary pathogen associated with Bovine Respiratory Disease (BRD) or "shipping fever" [Merck Veterinary Manual, 2023]. The most critical antigen is the leukotoxin (Lkt), a pore-forming exotoxin that specifically targets bovine leukocytes, leading to lung tissue damage and impaired immune response [Rice et al., 2007]. Other significant antigens include the capsular polysaccharide, which facilitates immune evasion, and various outer membrane proteins (OMPs) that mediate bacterial adhesion to the respiratory epithelium [Singh et al., 2011]. These antigens are the primary targets for veterinary vaccines, which utilize toxoids and surface proteins to elicit protective neutralizing antibodies and cell-mediated immunity [Griffin et al., 2010]. By targeting these specific bacterial components, therapeutic interventions aim to prevent the progression of fibrinous pleuropneumonia in ruminants. Effective management of these antigenic targets is essential for reducing the economic impact of respiratory infections in the livestock industry. Modern vaccine formulations often combine leukotoxoids with surface antigens to provide comprehensive protection. Understanding these antigens is crucial for developing effective immunotherapies and diagnostic tools for livestock health.
Vaccines containing these antigens stimulate the production of neutralizing antibodies and cell-mediated immune responses to prevent bacterial colonization and neutralize virulence factors like leukotoxin.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mannheimia haemolytica antigens.